menu
    • menu
    [{"orgOrder":0,"company":"United Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Dinutuximab","moa":"Disialoganglioside GD2","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"United Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"United Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Eusa Pharma","sponsor":"BeiGene","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Dinutuximab","moa":"Disialoganglioside GD2","graph1":"Oncology","graph2":"Approved","graph3":"Eusa Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"solution for infusion","sponsorNew":"Eusa Pharma \/ BeiGene","highestDevelopmentStatusID":"12","companyTruncated":"Eusa Pharma \/ BeiGene"},{"orgOrder":0,"company":"Eusa Pharma","sponsor":"Recordati","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Acquisition","leadProduct":"Dinutuximab","moa":"Disialoganglioside GD2","graph1":"Oncology","graph2":"Approved","graph3":"Eusa Pharma","amount2":0.84999999999999998,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0.84999999999999998,"dosageForm":"Infusion","sponsorNew":"Eusa Pharma \/ Recordati","highestDevelopmentStatusID":"12","companyTruncated":"Eusa Pharma \/ Recordati"},{"orgOrder":0,"company":"St. Jude Children\u2019s Research Hospital","sponsor":"Renaissance Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Dinutuximab","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"St. Jude Children\u2019s Research Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"St. Jude Children\u2019s Research Hospital \/ Renaissance Pharma","highestDevelopmentStatusID":"8","companyTruncated":"St. Jude Children\u2019s Research Hospital \/ Renaissance Pharma"},{"orgOrder":0,"company":"Essential Pharma","sponsor":"AGC Biologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Agreement","leadProduct":"Dinutuximab","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Essential Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Essential Pharma \/ AGC Biologics","highestDevelopmentStatusID":"8","companyTruncated":"Essential Pharma \/ AGC Biologics"},{"orgOrder":0,"company":"Apeiron Biologics","sponsor":"Ligand Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Acquisition","leadProduct":"Dinutuximab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Apeiron Biologics","amount2":0.13,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Apeiron Biologics \/ Ligand Pharmaceuticals","highestDevelopmentStatusID":"14","companyTruncated":"Apeiron Biologics \/ Ligand Pharmaceuticals"}]

    Find Clinical Drug Pipeline Developments & Deals for Dinutuximab

    Menu

    Dinutuximab

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Apeiron Biologics

                            Austria arrow
                            2024 ACI Convention
                            Not Confirmed

                            Apeiron Biologics

                            Austria arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dinutuximab

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Ligand Pharmaceuticals

                            Deal Size : $128.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Ligand to Acquire APEIRON Biologics AG for $100 Million

                            Details : Ligand acquires Apeiron Biologics pipeline which also includes Qarziba (dinutuximab beta), it is indicated for the treatment of high-risk neuroblastoma in patients aged 12 months and above.

                            Brand Name : Qarziba

                            Molecule Type : Large molecule

                            Upfront Cash : $100.0 million

                            July 08, 2024

                            Lead Product(s) : Dinutuximab

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Ligand Pharmaceuticals

                            Deal Size : $128.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Essential Pharma

                            United Kingdom arrow
                            2024 ACI Convention
                            Not Confirmed

                            Essential Pharma

                            United Kingdom arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dinutuximab,Cyclophosphamide,Topotecan Hydrochloride

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : AGC Biologics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Essential Pharma & AGC Biologics Partner for Immunotherapy Manufacturing for Neuroblastoma

                            Details : AGC Biologics will produce Hu1418K322A (Hu14.18), a humanised monoclonal antibody being developed for Essential Pharma for the treatment of high-risk neuroblastoma (HRNB).

                            Brand Name : Hu14.18K322A

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            June 11, 2024

                            Lead Product(s) : Dinutuximab,Cyclophosphamide,Topotecan Hydrochloride

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : AGC Biologics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            St. Jude Children’s Research Hospital

                            Country arrow
                            2024 ACI Convention
                            Not Confirmed

                            St. Jude Children’s Research Hospital

                            Country arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dinutuximab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Renaissance Pharma

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Renaissance Pharma Launches Today and Announces the In-Licensing of Hu14.18K322A (Hu14.18) from St. Jude Child...

                            Details : Under the agreement, Renaissance gains exclusive development, manufacturing and commercialisation rights for Hu14.18K322A, an anti GD2 humanised mAb in development by St. Jude for the treatment of newly diagnosed high-risk neuroblastoma.

                            Brand Name : Hu14.18K322A

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            August 01, 2023

                            Lead Product(s) : Dinutuximab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Renaissance Pharma

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Eusa Pharma

                            France arrow
                            2024 ACI Convention
                            Not Confirmed

                            Eusa Pharma

                            France arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dinutuximab

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Recordati

                            Deal Size : $847.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Recordati to Acquire Eusa Pharma (UK) Ltd, A Global Specialty Pharmaceutical Company Focused on Rare and Niche...

                            Details : Recordati will expand its pipeline by acquiring EUSA Pharma pipeline and enhances the breadth of indications which include Qarziba®, an anti-GD2 monoclonal antibody, Sylvant®, an anti-IL-6 monoclonal antibody, Fotivda®, an oral highly selective small ...

                            Brand Name : Qarziba

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            December 03, 2021

                            Lead Product(s) : Dinutuximab

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Recordati

                            Deal Size : $847.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Eusa Pharma

                            France arrow
                            2024 ACI Convention
                            Not Confirmed

                            Eusa Pharma

                            France arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dinutuximab

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : BeiGene

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            EUSA Pharma and BeiGene Announce Acceptance of a Biologics License Application for QARZIBA® (Dinutuximab Beta...

                            Details : QARZIBA® is a monoclonal antibody that is specifically directed against the carbohydrate moiety of disialoganglioside 2 (GD2), which is overexpressed on neuroblastoma cells.

                            Brand Name : Qarziba

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            November 09, 2020

                            Lead Product(s) : Dinutuximab

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : BeiGene

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            United Therapeutics

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            United Therapeutics

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dinutuximab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            United Therapeutics Announces Study of Unituxin® (dinutuximab)

                            Details : The DISTINCT trial did not meet its primary efficacy objective of extending the overall survival with Unituxin and irinotecan versus using irinotecan alone.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            February 03, 2020

                            Lead Product(s) : Dinutuximab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth